Massachusetts | 1-14041 | 04-2882273 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
400 Wood Road Braintree | MA 02184 |
Address of principal executive offices | (Zip Code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
(a) | Pro Forma Financial statements |
• | An Overview |
• | Unaudited Pro Forma Condensed Combined Balance Sheet as of June 30, 2012 |
• | Unaudited Pro Forma Condensed Combined Statement of Operations for the twelve months year ended March 31, 2012 |
• | Unaudited Pro Forma Condensed Combined Statement of Operations for the three months ended June 30, 2012 |
• | Notes to Unaudited Pro Forma Condensed Combined Financial Statements |
(b) | Financial statements |
• | Audited financial statements (statement of assets to be sold and liabilities to be assumed and statement of revenues and direct expenses) of the whole blood business as of July 31, 2011 and 2010 and for each of the three years in the period ended July 31, 2011and; |
• | Unaudited interim financial statements (statement of assets to be sold and liabilities to be assumed and statement of revenues and direct expenses) of the whole blood business as of April 30, 2012 and for the nine months ended April 30, 2012 |
Exhibit Number | Description | |
99.1 | Unaudited Pro Forma Condensed Combined Financial Information of Haemonetics Corporation. | |
99.2 | Audited financial statements of the whole blood business as of July 31, 2011 and 2010 and for each of the three years in the period ended July 31, 2011 | |
99.3 | Unaudited interim financial statements of the whole blood business as of April 30, 2012 and for the nine months ended April 30, 2012 |
Date: October 1, 2012 | Haemonetics Corporation | ||
By: | /S/ CHRISTOPHER LINDOP | ||
Christopher Lindop | |||
Chief Financial Officer and Vice President Business Development |
• | the accompanying notes to these unaudited pro forma condensed combined financial statements; |
• | the separate historical consolidated financial statements of Haemonetics as of and for the year ended March 31, 2012 and for the three months ended June 30, 2012 and July 2, 2011 filed on Forms 10-K and 10-Q with the SEC on May 22, 2012 and August 8, 2012 respectively; |
• | the separate historical consolidated financial statements of Haemonetics as of April 2, 2011 and April 3, 2010 and for each of the three years in the period ended April 2, 2011 both filed on Form 10-K with the SEC on May 26, 2011 and June 1, 2010 respectively; |
• | the separate historical unaudited interim financial statements (statement of assets to be sold and liabilities to be assumed and statement of revenues and direct expenses) of the whole blood business as of April 30, 2012 and for the nine months ended April 30, 2012 included in this filing; and |
• | the separate historical audited financial statements (statement of assets to be sold and liabilities to be assumed and statement of revenues and direct expenses) of the whole blood business as of July 31, 2011 and 2010 and for each of the three years in the period ended July 31, 2011also included in this filing. |
Unaudited Balance sheet Haemonetics | Unaudited Statement of assets to be sold and liabilities to be assumed | |||||||||||||||||||||
Corporation | The whole blood business | Pro forma | Pro forma | |||||||||||||||||||
June 30, 2012 | April 30, 2012 | Adjustments | Ref | Combined | ||||||||||||||||||
(Thousands of U.S. dollars, except share and per share amounts) | ||||||||||||||||||||||
ASSETS | ||||||||||||||||||||||
Current assets: | ||||||||||||||||||||||
Cash and cash equivalents | $ | 236,047 | $ | (66,596 | ) | A | $ | 169,451 | ||||||||||||||
Accounts receivable less allowance | 126,130 | 126,130 | ||||||||||||||||||||
Inventories, net | 126,843 | 41,273 | 10,662 | B | 178,778 | |||||||||||||||||
Prepaid expenses and other assets | 51,167 | 2,177 | 53,344 | |||||||||||||||||||
Total current assets | 540,187 | 43,450 | (55,934 | ) | 527,703 | |||||||||||||||||
Property, plant and equipment: | ||||||||||||||||||||||
Land, building, and building improvements | 55,533 | 28,133 | 43 | C | 83,709 | |||||||||||||||||
Plant equipment and machinery | 137,877 | 96,645 | 234,522 | |||||||||||||||||||
Office equipment and information technology | 94,982 | 5,268 | 100,250 | |||||||||||||||||||
Construction in progress | 13,690 | 13,690 | ||||||||||||||||||||
Haemonetics equipment | 229,763 | 229,763 | ||||||||||||||||||||
Total property, plant and equipment | 518,155 | 143,736 | 43 | 661,934 | ||||||||||||||||||
Less: accumulated depreciation | (351,915 | ) | (81,487 | ) | (433,402 | ) | ||||||||||||||||
Net property, plant and equipment | 166,240 | 62,249 | 43 | 228,532 | ||||||||||||||||||
Other assets: | ||||||||||||||||||||||
Intangible assets less amortization | 94,913 | 560 | 206,190 | D | 301,663 | |||||||||||||||||
Goodwill | 115,048 | 214,400 | E | 329,448 | ||||||||||||||||||
Other long-term assets | 11,735 | 5,596 | F | 17,331 | ||||||||||||||||||
Total assets | $ | 928,123 | $ | 106,259 | $ | 370,295 | $ | 1,404,677 | ||||||||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||||
Current liabilities: | ||||||||||||||||||||||
Notes payable less current portion | 2,417 | 2,417 | ||||||||||||||||||||
Accounts payable | 33,978 | 33,978 | ||||||||||||||||||||
Accrued payroll and related costs | 25,162 | 25,162 | ||||||||||||||||||||
Other liabilities | 60,349 | 1,554 | 61,903 | |||||||||||||||||||
Total current liabilities | 121,906 | 1,554 | — | 123,460 | ||||||||||||||||||
Long-term debt, net of current maturities | 2,642 | 475,000 | F | 477,642 | ||||||||||||||||||
Long-term deferred tax liability | 24,356 | 24,356 | ||||||||||||||||||||
Other long-term liabilities | 21,752 | 21,752 | ||||||||||||||||||||
Stockholders' equity: | ||||||||||||||||||||||
Common stock | 256 | 256 | ||||||||||||||||||||
Additional paid-in capital | 341,401 | 104,705 | (104,705 | ) | G | 341,401 | ||||||||||||||||
Retained earnings | 410,569 | 410,569 | ||||||||||||||||||||
Accumulated other comprehensive income | 5,241 | 5,241 | ||||||||||||||||||||
Total stockholders' equity | 757,467 | 104,705 | (104,705 | ) | 757,467 | |||||||||||||||||
Total liabilities and stockholders' equity | $ | 928,123 | $ | 106,259 | $ | 370,295 | $ | 1,404,677 |
Twelve months | |||||||||||||||
Audited Income Statement Haemonetics Corporation | Unaudited Statement of revenues and direct expenses The whole blood business | Pro forma | Pro forma | ||||||||||||
Adjustments | Combined | ||||||||||||||
March 31, 2012 | April 30, 2012 | Ref | |||||||||||||
Net revenues | $ | 727,844 | $ | 225,799 | $ | (10,000 | ) | H | $ | 943,643 | |||||
Cost of goods sold | 358,604 | 137,045 | (10,000 | ) | H | 485,649 | |||||||||
Gross profit | 369,240 | 88,754 | — | 457,994 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 36,801 | 5,790 | 42,591 | ||||||||||||
Selling, general and administrative | 245,261 | 23,250 | 31,222 | I | 299,733 | ||||||||||
Contingent consideration income | (1,580 | ) | (1,580 | ) | |||||||||||
Impairment charge | 7,336 | — | 7,336 | ||||||||||||
Total operating expenses | 280,482 | 36,376 | 31,222 | 348,080 | |||||||||||
Operating income | 88,758 | 52,378 | (31,222 | ) | 109,914 | ||||||||||
Interest expense | (9,520 | ) | J | (9,520 | ) | ||||||||||
Other income, net | 740 | — | 740 | ||||||||||||
Income before taxes | 89,498 | 52,378 | (40,742 | ) | 101,134 | ||||||||||
Provision for income taxes | 22,612 | 4,073 | K | 26,685 | |||||||||||
Net income | $ | 66,886 | $ | 52,378 | $ | (44,815 | ) | $ | 74,449 | ||||||
Basic income per common share | |||||||||||||||
Net income | $ | 2.64 | $ | 2.94 | |||||||||||
Income per common share assuming dilution | |||||||||||||||
Net income | $ | 2.59 | $ | 2.89 | |||||||||||
Weighted average shares outstanding | |||||||||||||||
Basic | 25,364 | 25,364 | |||||||||||||
Diluted | 25,795 | 25,795 |
Three months ended | |||||||||||||||||||||||
Unaudited Income Statement Haemonetics Corporation | Unaudited Statement of revenues and direct expenses The whole blood business | Pro forma | Pro forma | ||||||||||||||||||||
Adjustments | Combined | ||||||||||||||||||||||
June 30, 2012 | April 30, 2012 | Ref | |||||||||||||||||||||
Net revenues | $ | 176,475 | $ | 56,623 | $ | (2,500 | ) | H | $ | 230,598 | |||||||||||||
Cost of goods sold | 86,362 | 34,328 | (2,500 | ) | H | 118,190 | |||||||||||||||||
Gross profit | 90,113 | 22,295 | — | 112,408 | |||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Research and development | 9,409 | 1,405 | 10,814 | ||||||||||||||||||||
Selling, general and administrative | 67,625 | 5,819 | 7,805 | I | 81,249 | ||||||||||||||||||
Total operating expenses | 77,034 | 7,224 | 7,805 | 92,063 | |||||||||||||||||||
Operating income | 13,079 | 15,071 | (7,805 | ) | 20,345 | ||||||||||||||||||
Interest expense | (2,380 | ) | J | (2,380 | ) | ||||||||||||||||||
Other income, net | 336 | — | 336 | ||||||||||||||||||||
Income before taxes | 13,415 | 15,071 | (10,185 | ) | 18,301 | ||||||||||||||||||
Provision for income taxes | 3,628 | 1,710 | K | 5,338 | |||||||||||||||||||
Net income/Loss | $ | 9,787 | $ | 15,071 | $ | (11,895 | ) | $ | 12,963 | ||||||||||||||
Basic income per common share | |||||||||||||||||||||||
Net income | $ | 0.38 | $ | 0.51 | |||||||||||||||||||
Income per common share assuming dilution | |||||||||||||||||||||||
Net income | $ | 0.38 | $ | 0.50 | |||||||||||||||||||
Weighted average shares outstanding | |||||||||||||||||||||||
Basic | 25,483 | 25,483 | |||||||||||||||||||||
Diluted | 25,932 | 25,932 |
Estimated cash to be paid to Pall | $ | 536,000 |
Purchase Price Allocation | |||
Book value of net assets acquired on August 1, 2012 | $ | 104,705 | |
Less: the whole blood business' historical intangible assets | (560 | ) | |
Adjusted book value of assets acquired | 104,145 | ||
Remaining allocation: | |||
Increase property and equipment to fair value (a) | 43 | ||
Increase inventory to fair value (b) | 10,662 | ||
Identifiable intangible assets (c) | 206,750 | ||
Goodwill (d) | 214,400 | ||
Estimated purchase price | $ | 536,000 |
Estimated Fair Value | Weighted average useful life | ||||
Customer relationships | $ | 144,725 | 10 years | ||
Existing technology | 62,025 | 10 years | |||
$ | 206,750 |
Cash proceeds received from debt financing (a) | $ | 475,000 | |
Cash payment made to Pall Corporation (b) | (536,000 | ) | |
Estimated deferred financing costs | (5,596 | ) | |
Gross cash disbursed to fund the transaction | $ | (66,596 | ) |
(B) Adjust acquired inventory to an estimate of fair value. In the periods following consummation of the Acquisition, Haemonetics cost of revenue will reflect the increased valuation of the whole blood business' inventory as the acquired inventory is sold, which for purposes of these unaudited pro forma condensed combined financial statements is assumed will occur within the first year post-acquisition. This is considered a non-recurring adjustment with no continuing impact on the combined operating results and as such is not included in the unaudited pro forma condensed combined statement of income. | $ | 10,662 | |
(C) Adjust for the estimated difference between the book value and the fair value of net property, plant and equipment. See Note 3(a). | $ | 43 |
Estimated acquired intangible assets | $ | 206,750 | |
Eliminate the whole blood business historical intangible assets | (560 | ) | |
Intangible assets adjustment | $ | 206,190 |
Estimated transaction goodwill (Note 3d) | $ | 214,400 |
Year Ended March 31, 2012 | Three Months Ended June 30, 2012 | ||||||
Additional Cost to operate the expanded company (a) | $ | 10,540 | $ | 2,635 | |||
Depreciation on property, plant and equipment fair value adjustment | $ | 6 | $ | 1 | |||
Amortization of acquired intangible assets related to technology and customer relationships | 20,876 | 5,219 | |||||
Elimination of the whole blood business' historical intangible asset amortization | (200 | ) | (50 | ) | |||
$ | 31,222 | $ | 7,805 |
Year Ended March 31, 2012 | Three Months Ended June 30, 2012 | ||||||
Cash interest on the Credit Facilities (a) | $ | (8,133 | ) | $ | (2,033 | ) | |
Deferred financing costs | (1,387 | ) | $ | (347 | ) | ||
$ | (9,520 | ) | $ | (2,380 | ) |
Audited Financial Statements: | Page | ||
Independent Auditors' Report | 1 | ||
Statements of Assets to be Sold and Liabilities to be Assumed as of July 31, 2011 and July 31, 2010 | 2 | ||
Statements of Revenues and Direct Expenses for the years ended July 31, 2011 July 31, 2010 and July 31, 2009 | 3 | ||
Notes to Financial Statements | 4 | ||
July 31, | July 31, | |||||
2011 | 2010 | |||||
Current assets to be sold: | ||||||
Inventory | $ | 37,125 | 40,300 | |||
Other current assets | 2,189 | 1,485 | ||||
Total current assets to be sold | 39,314 | 41,785 | ||||
Property, plant and equipment | 64,567 | 69,298 | ||||
Intangible assets | 683 | 845 | ||||
Other noncurrent assets | 103 | 145 | ||||
Total assets to be sold | 104,667 | 112,073 | ||||
Total liabilities to be assumed | 1,817 | 1,719 | ||||
Net assets to be sold | $ | 102,850 | 110,354 | |||
See accompanying notes to financial statements. |
Years ended | |||||||||
July 31, | July 31, | July 31, | |||||||
2011 | 2010 | 2009 | |||||||
Net sales | $ | 223,721 | 216,253 | 209,557 | |||||
Cost of sales | 136,243 | 131,697 | 134,053 | ||||||
Gross profit | 87,478 | 84,556 | 75,504 | ||||||
Selling, general and administrative expenses | 23,166 | 23,282 | 24,262 | ||||||
Research and development | 6,299 | 6,148 | 6,433 | ||||||
Asset impairment charges | 7,336 | — | — | ||||||
Revenues in excess of direct expenses | $ | 50,677 | 55,126 | 44,809 | |||||
See accompanying notes to financial statements. |
(2) | Summary of Significant Accounting Policies |
(a) | Inventory |
(b) | Long‑Lived Assets |
(c) | Revenue Recognition |
(d) | Cost of Sales |
(e) | Selling and Marketing Expenses |
(f) | General and Administrative Expenses |
(g) | Research and Development Expenses |
2011 | 2010 | |||||
Raw materials and components | $ | 14,169 | 13,008 | |||
Work-in-process | 2,329 | 3,704 | ||||
Finished goods | 20,627 | 23,588 | ||||
$ | 37,125 | 40,300 |
(4) | Property, Plant and Equipment |
2011 | 2010 | |||||
Land | $ | 1,491 | 1,491 | |||
Buildings and improvements | 27,361 | 31,361 | ||||
Machinery and equipment | 93,908 | 102,008 | ||||
Construction in progress | 13,668 | 15,708 | ||||
Information technology hardware and software | 3,064 | 2,777 | ||||
Furniture and fixtures | 1,649 | 1,623 | ||||
141,141 | 154,968 | |||||
Less accumulated depreciation and amortization | (76,574 | ) | (85,670 | ) | ||
$ | 64,567 | 69,298 |
2011 | |||||||||
Accumulated | |||||||||
Gross | amortization | Net | |||||||
Patents | $ | 2,605 | 1,943 | 662 | |||||
Trademarks | 84 | 63 | 21 | ||||||
$ | 2,689 | 2,006 | 683 |
2010 | |||||||||
Accumulated | |||||||||
Gross | amortization | Net | |||||||
Patents | $ | 2,621 | 1,798 | 823 | |||||
Trademarks | 84 | 61 | 22 | ||||||
$ | 2,704 | 1,859 | 845 |
(6) | Contingencies and Commitments |
(7) | Asset Impairment Charges |
(8) | Subsequent Events |
Unaudited Interim Financial Statements: | Page | ||
Unaudited Statements of Assets to be Sold and Liabilities to be Assumed as of April 30, 2012 and July 31, 2011 | 1 | ||
Unaudited Statements of Revenues and Direct Expenses for the nine months ended April 30, 2012 and April 30, 2011 | 2 | ||
Notes to Unaudited Interim Financial Statements | 3 | ||
BLOOD COLLECTION, FILTRATION AND | ||||||
PROCESSING PRODUCT LINE | ||||||
(A Component of Pall Corporation) | ||||||
Statements of Assets to be Sold and Liabilities to be Assumed | ||||||
(Unaudited) | ||||||
(In thousands) | ||||||
April 30, | July 31, | |||||
2012 | 2011 | |||||
Current assets to be sold: | ||||||
Inventory | $ | 41,273 | 37,125 | |||
Other current assets | 2,177 | 2,189 | ||||
Total current assets to be sold | 43,450 | 39,314 | ||||
Property, plant and equipment | 62,249 | 64,567 | ||||
Intangible assets | 560 | 683 | ||||
Other non-current assets | — | 103 | ||||
Total assets to be sold | 106,259 | 104,667 | ||||
Total liabilities to be assumed | 1,554 | 1,817 | ||||
Net assets to be sold | $ | 104,705 | 102,850 | |||
See accompanying notes to interim financial statements. |
BLOOD COLLECTION, FILTRATION AND | ||||||
PROCESSING PRODUCT LINE | ||||||
(A Component of Pall Corporation) | ||||||
Statements of Revenues and Direct Expenses | ||||||
(Unaudited) | ||||||
(In thousands) | ||||||
Nine months ended | ||||||
April 30, | April 30, | |||||
2012 | 2011 | |||||
Net sales | $ | 169,869 | 162,038 | |||
Cost of sales | 102,984 | 98,411 | ||||
Gross profit | 66,885 | 63,627 | ||||
Selling, general and administrative expenses | 17,458 | 16,956 | ||||
Research and development | 4,215 | 4,800 | ||||
Revenues in excess of direct expenses | $ | 45,212 | 41,871 | |||
See accompanying notes to interim financial statements. |
(1) | Description of Business and Basis of Presentation |
(a) | Background and Description of Business |
(b) | Basis of Presentation |
(2) | Inventory |
April 30, | July 31, | |||||
2012 | 2011 | |||||
Raw materials and components | $ | 13,507 | 14,169 | |||
Work-in-process | 4,441 | 2,329 | ||||
Finished goods | 23,325 | 20,627 | ||||
$ | 41,273 | 37,125 |
(3) | Property, Plant and Equipment |
April 30, | July 31, | |||||
2012 | 2011 | |||||
Land | $ | 1,491 | 1,491 | |||
Buildings and improvements | 26,642 | 27,361 | ||||
Machinery and equipment | 96,645 | 93,908 | ||||
Construction in progress | 13,690 | 13,668 | ||||
Information technology hardware and software | 3,038 | 3,064 | ||||
Furniture and fixtures | 2,230 | 1,649 | ||||
143,736 | 141,141 | |||||
Less accumulated depreciation and amortization | (81,487 | ) | (76,574 | ) | ||
$ | 62,249 | 64,567 |
(4) | Intangible Assets |
April 30, 2012 | |||||||||
Accumulated | |||||||||
Gross | amortization | Total | |||||||
Patents | $ | 2,590 | 2,048 | 542 | |||||
Trademarks | 84 | 66 | 18 | ||||||
$ | 2,674 | 2,114 | 560 |
July 31, 2011 | |||||||||
Accumulated | |||||||||
Gross | amortization | Total | |||||||
Patents | $ | 2,605 | 1,943 | 662 | |||||
Trademarks | 84 | 63 | 21 | ||||||
$ | 2,689 | 2,006 | 683 |
(5) | Contingencies and Commitments |
(6) | Subsequent Events |